<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
Filed pursuant to Section 13 or 15(d) of the Securities
Exchange act of 1934 and Rule 13a-17 or 154-17 thereunder
ABIOMED, Inc.
(Exact name of Issuer as specified in charter)
33 Cherry Hill Drive, Danvers, Massachusetts 01923
(Address of principal executive offices)
Issuer s telephone number, including area code (508) 777-5410
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% or more in the number
of shares outstanding:
1. Title of security Common Stock
2. Number of shares outstanding before the change 5,542,266
3. Number of shares outstanding after the change 6,970,266
4. Effective date of change July 31, 1996 ____
5. Method of change:
Specify method (such as merger, acquisition, exchange, distribution, stock
split, reverse split, acquisition of stock for treasury, etc.)
Conversion of Class A Common Stock
Give brief description of transaction Shares are being issued in connection
with the conversion of 1,428,000 Shares of Class A Common Stock into an equal
number of shares of Common Stock.
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
2. Name after change
3. Effective date of charter amendment changing name
4. Date of shareholder approval of change, if required
July 31, 1996 /s/ John F. Thero______________________________
Date John F. Thero, Vice President Finance and
Chief Financial Officer
